Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

Completed · Phase 4

Conditions studied: Cystinuria

In brief

The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.

Key facts

Study ID

NCT02125721

Run by

NYU Langone Health

People needed

10

Starts

2012-06-01

Expected to finish

2017-12-01

Last updated by the study team

2021-08-23

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be a patient with a confirmed diagnosis of cystinuria.
• Be already taking a CBTD (either D-penicillamine (Cuprimine®) or tiopronin (Thiola®) as part of your medication regimen.
• Be between 18 and 80 years of age
• Be enrolled in the Cystinuria Registry.

You may not qualify if…

• You are not a patient with cystinuria
• You are not already taking a cystine binding thiol drug
• You have renal colic (if you are passing a stone)
• You are scheduled to undergo a urologic procedure
• You are unwilling or unable to provide informed consent in order to be able to participate.

Where it is running

• NYU Langone Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.